Objective: To investigate the frequency of, risk factors for, and outcomes after elevated levels of vancomycin. Patients and Methods: We identified hospitalizations among 21,285 individuals in which intravenous vancomycin was given between August 29, 2007, and October 10, 2014. We investigated frequency and risk factors for elevated vancomycin levels (trough levels >30 mg/L) as well as associations with subsequent acute kidney injury (AKI), length of stay, and in-hospital mortality. Results: Among the 21,285 patients, the mean age was 62.9 years, and 10,478 (49.2%) were female. Trough levels of vancomycin were checked in 7422 patients, and 755 elevated levels were detected. Compared with patients with trough levels checked but no elevated levels found, those with elevated levels had longer duration of vancomycin therapy (median, 6.0 days vs 3.4 days; P<.001) and slightly higher doses (mean, 1.72 g vs 1.58 g; P<.001). Patients with higher body mass index or lower estimated glomerular filtration rate had more elevated levels. In propensity-matched analyses, patients had higher risk of incident AKI after elevated levels compared with patients without elevated levels (hazard ratio, 1.55; 95% CI, 1.09-2.20; P¼.02), as well as longer subsequent length of stay (relative risk, 1.14; 95% CI, 1.02-1.28; P¼.03) but similar in-hospital mortality. Conclusion: In this study, elevated vancomycin levels were common, particularly in patients with higher body mass index and lower estimated glomerular filtration rate, and were associated with greater subsequent AKI and length of stay. 
V
ancomycin, a glycopeptide antibiotic that inhibits cell wall synthesis in gram-positive bacteria, is one of the most commonly used intravenous (IV) antibiotics in the world. 1 Its use has increased since the epidemic of methicillin-resistant Staphylococcus aureus (MRSA) infections began in the 1990s; currently, MRSA infections affect approximately 80,000 hospitalizations and cause 11,000 related deaths in the United States each year. 2, 3 Vancomycin is the guideline-recommended, first-line antibiotic for invasive MRSA infections. 4 Given the widespread use of vancomycin, quantifying the risk of and risk factors for vancomycin-related complications is important.
One potential but controversial adverse effect of vancomycin is nephrotoxicity resulting in acute kidney injury (AKI). [5] [6] [7] The mechanism of injury may be formation of reactive oxygen species, mitochondrial dysfunction, and apoptosis leading to injury and death of cells of the proximal tubular epithelium, loop of Henle, and collecting duct; kidney biopsies have revealed acute tubular necrosis, cast nephropathy, and also acute interstitial nephritis and noncaseating granulomas. [8] [9] [10] [11] [12] [13] Regardless of cause, patients who sustain AKI face a higher risk of subsequent morbidity, including estimated glomerular filtration rate (eGFR) decline, chronic kidney disease, cardiovascular events, and mortality.
Much of the suspected vancomycin nephrotoxicity is thought to be iatrogenic and related to elevated blood levels. Previous studies have found trough levels greater than 15 mg/L to be predictive of nephrotoxicity. 5, 17, 18 However, many guideline organizations recommend a trough vancomycin concentration of between 15 and 20 mg/L, particularly for complicated infections such as bacteremia, endocarditis, osteomyelitis, meningitis, and hospital-acquired pneumonia caused by MRSA, with a minimum trough level of 10 mg/L to avoid development of vancomycin resistance. 4, 7 Thus, keeping vancomycin trough levels within a therapeutic range is of high priority both for antimicrobial effectiveness and for avoidance of toxicity.
Using community-based data from a large health care system, we investigated the frequency of, risk factors for, and outcomes after elevated levels of vancomycin in the inpatient setting, testing the hypotheses that (1) elevated trough levels (>30 mg/ L) are common, (2) obesity (body mass index [BMI; calculated as weight in kilograms divided by height in meters squared] >30 kg/m 2 ) and eGFR less than 60 mL/min per 1.73 m 2 are risk factors for elevated vancomycin levels, and (3) elevated trough levels are associated with higher subsequent morbidity, including AKI and longer hospital length of stay.
PATIENTS AND METHODS

Study Population
We conducted a retrospective cohort study of primary care patients over 18 years of age in the Geisinger Health System. From this population, we identified 21,285 individuals who received IV vancomycin during a hospitalization in a Geisinger hospital between August 29, 2007 , and October 10, 2014. If a patient had multiple qualifying hospitalizations, we selected the first hospitalization in which vancomycin was given (Supplemental Figure 1 , available online at http://www.mayoclinicproceedings.org). Geisinger Health System serves more than 3 million residents throughout 45 counties in central and northeastern Pennsylvania and has 12 hospital campuses with a 551,000-member health plan, all with an integrated electronic medical record. This study was deemed exempt by the Geisinger Medical Center Institutional Review Board as well as the Johns Hopkins University Institutional Review Board.
Vancomycin Dose and Levels
Information on IV vancomycin use was abstracted from the electronic medication administration records. Records with incomplete or invalid dose information (eg, single doses <250 mg or >4 g) were excluded. When multiple dosages were given, the maximum administered dose was recorded. Dosing intervals were determined empirically among patients who received at least 3 doses. Trough levels were defined as a vancomycin check at least 8 hours after the last dose. Because guidelines have varied on optimal target trough levels 19 and the somewhat broad definition of trough used, elevated vancomycin levels were defined conservatively as trough levels greater than 30 mg/L. A sensitivity analysis was conducted using a lower cutoff (>20 mg/L). If multiple levels qualified as elevated, the first was considered the index event.
Covariate Definitions
We abstracted data from the electronic medical record on age, sex, race, BMI, and serum creatinine (which was converted to eGFR using the equation developed by the Chronic Kidney Disease Epidemiology Collaboration 20 ). Baseline eGFR was considered the closest antecedent value to vancomycin start date, excluding any value that was measured more than 3 days before the admission date. However, all creatinine values during the hospitalization were evaluated for the purpose of determining the onset of AKI episodes. Body mass index was defined as the closest outpatient value before admission. History of hypertension, diabetes mellitus, congestive heart failure, and atherosclerotic cardiovascular disease (myocardial infarction, stroke, or peripheral vascular disease) was identified from inpatient and outpatient electronic health records using International Classification of Diseases, Ninth Revision, Clinical Modification diagnostic codes. Information on intensive care unit level of care during hospitalization was extracted from hospitalization records. International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes were used to identify sepsis and MRSA infection. Specific coding algorithms are provided in Supplemental Table 1 (available online at http://www.mayoclinicproceedings.org).
Adverse Event Definitions
We defined AKI according to the Kidney Disease Improving Global Outcomes (KDIGO) guideline, which is an increase in serum creatinine of 0.3 mg/dL within 48 hours or 50% within 7 days, and determined if the AKI event preceded or followed the elevated vancomycin level. 21 To assess incident AKI after elevated vancomycin levels, we excluded patients with AKI that occurred earlier in the hospitalization ("history of AKI"). In sensitivity analysis, we evaluated KDIGO stage 2 or worse AKI following the elevated vancomycin level. We also evaluated the length of hospital stay after reaching an elevated vancomycin level as well as inhospital mortality.
Statistical Analyses
Baseline characteristics of patients who received IV vancomycin were compared using analysis of variance for continuous variables and c 2 tests for categorical variables. In analyses by BMI category and eGFR stage, P for trend was estimated using linear, quantile, and logistic regression to evaluate the trend of means, median, and proportion, respectively, within categories. The relationship between vancomycin levels during hospitalization and adverse outcomes after that level was assessed using Cox proportional hazards regression for time to AKI and time to mortality and negative binomial regression for length of stay. These analyses were done using the first elevated level (for patients with an elevated level) or maximum vancomycin trough level (for all others). Vancomycin level was treated as a continuous variable with adjustment for age, sex, race, BMI, eGFR, diabetes, hypertension, cardiovascular disease, heart failure, sepsis, intensive care unit admission, and length of stay before the vancomycin admission. Then, to additionally address confounders of elevated vancomycin level, propensity scores using the same variables were constructed to match patients with elevated levels to those with trough levels less than 30 mg/L. Cases (elevated vancomycin levels) were matched to controls 1:1 without replacement with calipers set to a quarter of the standard deviation of the calculated propensity scores. Cases and controls were matched exactly on a history of AKI before vancomycin level (these patients were excluded from analyses of incident AKI) and vancomycin therapy duration before the level. Time at risk began at first elevated trough level among cases and at the matched nonelevated trough level in controls. Analyses were conducted in a propensity scoreematched sample and in a second model adjusting for covariates that differed between cases and controls. To address the absence of baseline BMI and eGFR (missing in 2033 [9.6%] and 1321 [6.2%] of the 21,285 patients, respectively), we used mean imputation using baseline covariates for adjusted analyses. To increase confidence that the creatinine elevation occurred subsequent to the elevated vancomycin level, we performed sensitivity analyses only among patients with serum creatinine levels checked within 24 hours before the elevated trough level. All analyses were conducted using Stata statistical software, version 14.2 (StataCorp).
RESULTS
Study Population
We identified 21,285 patients with hospitalizations in which IV vancomycin was administered. Of these, 8136 patients had a vancomycin level assessment during hospitalization, and 7422 had an assessment of a vancomycin trough level (Supplemental Table 2 , available online at http://www. mayoclinicproceedings.org). The mean AE SD age of the 7422 patients was 64.2AE16.0 years, 3297 (44.4%) were female, 2886 (38.9%) had a history of diabetes mellitus, and 3707 (49.9%) had a history of cardiovascular disease (Table 1 Elevated Vancomycin Trough Levels Elevated trough levels (vancomycin levels >30 mg/L) occurred in 755 of the 7422 patients in whom trough levels were assessed (10.2%). Nearly half of the patients with elevated trough levels (371 of 755 [49.1%]) had a previous checked trough level that was 30 mg/L or lower. Elevated trough levels occurred more frequently in younger individuals, women, and those with diabetes or heart failure. Compared with patients with trough levels checked but no elevated levels found, those with elevated levels had longer duration of vancomycin therapy (median, 6.0 days vs 3.4 days; P<.001) and slightly higher doses (mean, 1.72 g vs 1.58 g; P<.001) ( Table 2) . Among the 1668 patients who had trough monitoring and more than 7 days of vancomycin therapy, 332 (19.9%) had elevated levels.
Trends in Vancomycin Dosing Patterns and Levels by BMI and eGFR Categories
The duration of vancomycin therapy was similar across BMI categories, but the maximum dose of vancomycin increased with higher BMI, although the opposite was true for weight-based dose (Table 3 ). There was a trend toward a greater proportion of elevated vancomycin levels in patients with higher BMI (P<.001). For example, among the patients with a BMI of less than 20 kg/ m 2 , 29 of 418 in whom trough level was checked (6.9%) had elevated levels of vancomycin, compared with 136 of 969 in whom tough level was checked (14.0%) in people with BMI !40 kg/m 2 . Within categories of eGFR, the duration of vancomycin therapy was slightly longer with lower eGFR. The maximum dose of vancomycin was higher with lower eGFR, but the weight-based daily dose was lower. The proportion of patients with elevated levels was 8.3% (134 of 1621 in whom trough level was checked) among those with a eGFR of 90 mL/min per 1.73 m 2 or higher and 12.7% (221 of 1741 in whom trough level was checked) among those with an eGFR of less than 30 mL/min per 1.73 m 2 . Both low eGFR and higher BMI remained as significant risk factors for elevated levels in adjusted analyses (data not shown).
Association of Vancomycin Levels With Time to Subsequent AKI and Length of Stay
When vancomycin trough level was considered a continuous variable, higher levels were associated with greater risk of adverse outcomes. After excluding the 4618 patients 
Risks Associated With Elevated Vancomycin
Trough Levels in the Propensity-Matched Cohort There were 679 patients with elevated trough levels who were successfully matched to 679 other patients without elevated trough levels, 397 of whom in each group had AKI before the elevated trough level (Supplemental Tables 3 and 4 , available online at http:// www.mayoclinicproceedings.org). Among those without prior AKI, there were 82 subsequent AKI cases among patients with an elevated trough level and 51 among those without elevated trough levels. Most of the stage 1 AKI cases (79 [96.3%]) occurred within 24 hours of the elevated trough level. A vancomycin trough level higher than 30 mg/L was associated with a higher hazard of subsequent AKI stage 1 or worse (hazard ratio, 1.55; 95% CI, 1.09-2.20; P¼.02) and stage 2 or worse (hazard ratio, 2.31; 95% CI, 1.06-5.03) ( Table 4 ). Sensitivity analyses requiring that a serum creatinine level be checked within 24 hours before the vancomycin trough level yielded similar results (hazard ratio for subsequent AKI stage 1 or worse, 1.57; 95% CI, 1.10-2.25; stage 2 or worse, 2.30; 95% CI, 1.01-5.26). Among the full matched cohort, a trough level of vancomycin higher than 30 mg/L was associated with longer hospital length of stay (relative risk, 1.14; 95% CI, 1.02-1.28; P¼.03) but not higher risk of mortality (hazard ratio, 1.18; 95% CI, 0.88-1.58). Risk associations with elevated levels of vancomycin were slightly attenuated when using a lower cutoff point (trough level >20 mg/L) (Supplemental Table 5 , available online at http://www. mayoclinicproceedings.org).
DISCUSSION
Using data from a large health care system, we found that supratherapeutic vancomycin levels occurred in 10.2% of hospitalizations with a vancomycin trough level checked and in nearly 20% of those in whom vancomycin was given for more than 7 days. Higher BMI and lower eGFR were strong risk factors for supratherapeutic levels, 22 A prospective study of 95 patients with MRSA infections found that nephrotoxicity was higher with longer duration of vancomycin therapy: 6% for 7 or fewer days, 21% for 8 to 14 days, and 30% for more than 14 days. 23 A study of 94 patients revealed a 2.6-fold higher odds of nephrotoxicity with 2 or more weeks of therapy compared with vancomycin therapy of shorter duration. 24 A study of 291 patients found that higher-dose vancomycin regimens (!4 g/d) had higher likelihood of nephrotoxicity compared with lower-dose regimens or linezolid (34.6%, 10.9%, and 6.7%, respectively). 25 A study of 11,650 patients investigated differences in AKI incidence in those receiving vancomycin alone, piperacillin-tazobactam alone, or combination therapy, finding that combination therapy resulted in double the odds of AKI compared with either therapy alone. 26 However, most of these studies did not assess trough levels, the definitions of nephrotoxicity varied, and attributing toxicity to vancomycin therapy can be subjective. Our study adds to the existing literature by reporting the occurrence of elevated levels and using propensity matching to ascertain the risk of subsequent AKI, longer hospital stay, and in-hospital mortality.
A priori, we hypothesized that 2 risk factorsdhigher BMI and lower eGFRdwould be associated with higher occurrence of elevated vancomycin levels. We expected that elevated levels might occur more frequently in those with higher BMI because vancomycin dosing is partly based on total body weight and pharmacists often determine dose with use of the Cockcroft-Gault formula, which overestimates glomerular filtration rate at higher levels of BMI. 7 A previous report 27 found that 64% of vancomycin levels exceeding 20 mg/L occurred in patients weighing more than 100 kg; another report 28 suggested that adherence to the Infectious Diseases Society of America guideline resulted in more supratherapeutic vancomycin levels in patients with a BMI greater than 35 kg/m 2 . Our study found that mean dose was higher but that weightbased daily dose was lower with higher BMI and that risk of elevated levels more than doubled from BMI less than 20 kg/m 2 to BMI greater than 40 kg/m 2 , suggesting that dosing in morbid obesity may require titration. Lastly, because of the renal clearance of vancomycin, we expected (and found) higher risk of elevated levels in patients with lower eGFR. Surprisingly, maximum dose of vancomycin was slightly higher with lower eGFR.
A strength of our study is the large study population with extensive clinical data. Most previous studies had far fewer patients; even a recent meta-analysis included only 4033 patients. 29 However, our study has certain limitations. The temporal sequence of elevated trough levels and AKI is difficult to characterize perfectly because we are limited by when creatinine and vancomycin levels were checked. Most of our AKI cases occurred within a day after the vancomycin trough level was obtained. However, most patients had creatinine level checked within 24 hours before the trough level, and sensitivity analyses including only those patients had similar results. We cannot determine causality. Patients with supratherapeutic levels of vancomycin may be at higher risk of AKI and longer length of stay for reasons unrelated to the vancomycin level. We attempted to address this possible bias by performing propensity matching, but there remains potential for residual confounding. Vancomycin trough timing is notoriously variable, 30 and we chose a broad definition. However, coupled with a relatively conservative definition of elevated vancomycin levels, we believe our specificity is high. Finally, much has changed over the study period, including dosing practices, the definition of AKI, and the rapidity with which antimicrobial sensitivities are reported. 7, 21 For these reasons, we chose trough levels of vancomycin as our exposure of interest and identified AKI by change in creatinine level rather than diagnostic code. Still, our pharmacokinetic data are limited to what was checked in routine practice.
CONCLUSION
We found that elevated vancomycin levels were common and occurred more frequently when vancomycin was given for more than 7 days, when BMI was high, and when eGFR was low. Further, elevated levels of vancomycin were associated with higher risk of AKI and longer hospital stays. Given the increasing use of IV vancomycin worldwide and the potential for nephrotoxicity, careful use and monitoring of vancomycin therapy, particularly in overweight/obese patients or those with chronic kidney disease, may substantially reduce in-hospital morbidity.
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